Sep 21, 2026 8 0
Uploaded by Violet
Favorite
Share
More Options
12
Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US_Page 1

Open in WPS to view all 12 pages